NewLimit
David Reynolds is a Senior Scientist at NewLimit since July 2022, bringing extensive research experience from a Postdoctoral Fellow position at Stanford University held from June 2016 to June 2022. David earned a Doctor of Philosophy in Biochemistry and Molecular Biology from The University of Georgia, where studies were completed in June 2016. Prior educational accomplishments include a Bachelor's degree in Biology from the University of Virginia, obtained in May 2010.
This person is not in the org chart
This person is not in any teams
NewLimit
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.